7 vs 14 Days of Antibiotics for Bacteremia, Factor XI Inhibition for Atrial Fibrillation, ACEi or ARB Before Elective Surgery, GLP-1 Agonist for HFpEF and Obesity
Last Week in Medicine
00:00
Exploring GLP-1 Agonists for Heart Health
This chapter examines the promising role of GLP-1 agonists, particularly terzepatide, in treating heart failure with preserved ejection fraction (HFpEF) and obesity, as evidenced by the recent SUMMIT trial. It discusses the significant improvements observed in cardiovascular outcomes and symptom management alongside potential gastrointestinal side effects. The conversation also highlights the implications for future heart failure treatment guidelines and personal experiences with these medications.
Play episode from 48:31
Transcript
